Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. 

But the company posted a modest 2026 outlook that fell short of Wall Street's expectations as it prepares for a few drugs to lose paten...